miR-34a is upregulated inAIP-mutated somatotropinomas and promotes octreotide resistance by Bogner, Eva-Maria et al.
MOL E CU L A R C AN C E R B I O L OG Y
miR-34a is upregulated in AIP-mutated somatotropinomas
and promotes octreotide resistance
Eva-Maria Bogner1 | Adrian F. Daly2 | Sebastian Gulde1 | Auli Karhu3 |
Martin Irmler4 | Johannes Beckers4,5,6 | Hermine Mohr1 | Albert Beckers2 |
Natalia S. Pellegata1
1Institute for Diabetes and Cancer, Helmholtz
Zentrum München, Neuherberg, Germany
2Department of Endocrinology, Centre
Hospitalier Universitaire de Liège, Liège
Université, Liège, Belgium
3Department of Medical and Clinical
Genetics & Genome-Scale Biology Research
Programs Unit, University of Helsinki, Helsinki,
Finland
4Institute of Experimental Genetics, Helmholtz
Zentrum München, Neuherberg, Germany
5Technische Universität München, Chair of
Experimental Genetics, Freising, Germany
6German Center for Diabetes Research (DZD),
Neuherberg, Germany
Correspondence
Natalia S. Pellegata, Institute for Diabetes and
Cancer, Helmholtz Zentrum München,
Ingolstaedter Landstrasse 1, 85764
Neuherberg, Germany.
Email: natalia.pellegata@helmholtz-
muenchen.de
Funding information
Deutsche Forschungsgemeinschaft, Grant/
Award Number: TRR 205/B11; Deutsche
Krebshilfe, Grant/Award Number: 70112383;
Abstract
Pituitary adenomas (PAs) are intracranial tumors associated with significant morbidity
due to hormonal dysregulation, mass effects and have a heavy treatment burden.
Growth hormone (GH)-secreting PAs (somatotropinomas) cause acromegaly-gigan-
tism. Genetic forms of somatotropinomas due to germline AIP mutations (AIPmut+)
have an early onset and are aggressive and resistant to treatment with somatostatin
analogs (SSAs), including octreotide. The molecular underpinnings of these clinical
features remain unclear. We investigated the role of miRNA dysregulation in AIPmut
+ vs AIPmut− PA samples by array analysis. miR-34a and miR-145 were highly
expressed in AIPmut+ vs AIPmut− somatotropinomas. Ectopic expression of AIPmut
(p.R271W) in Aip−/− mouse embryonic fibroblasts (MEFs) upregulated miR-34a and
miR-145, establishing a causal link between AIPmut and miRNA expression. In PA
cells (GH3), miR-34a overexpression promoted proliferation, clonogenicity, migration
and suppressed apoptosis, whereas miR-145 moderately affected proliferation and
apoptosis. Moreover, high miR-34a expression increased intracellular cAMP, a critical
mitogenic factor in PAs. Crucially, high miR-34a expression significantly blunted
octreotide-mediated GH inhibition and antiproliferative effects. miR-34a directly tar-
gets Gnai2 encoding Gαi2, a G protein subunit inhibiting cAMP production. Accord-
ingly, Gαi2 levels were significantly lower in AIPmut+ vs AIPmut− PA. Taken
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together, somatotropinomas with AIP mutations overexpress miR-34a, which in turn
downregulates Gαi2 expression, increases cAMP concentration and ultimately pro-
motes cell growth. Upregulation of miR-34a also impairs the hormonal and antip-
roliferative response of PA cells to octreotide. Thus, miR-34a is a novel downstream
target of mutant AIP that promotes a cellular phenotype mirroring the aggressive clin-
ical features of AIPmut+ acromegaly.
K E YWORD S
aryl hydrocarbon receptor-interacting protein, G protein subunit alpha i2, miR-34a, octreotide
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1 | INTRODUCTION
Pituitary adenomas (PAs) comprise up to 15% of intracranial tumors
and clinically relevant PAs occur in approximately 1:1000 of the gen-
eral population.1,2 They represent a challenging health burden due to
disordered hormonal function and tumor growth; PA treatments are
invasive, costly and require significant expertise.3 PAs usually occur
sporadically but about 5% of cases present as part of hereditary syn-
dromes, like familial isolated pituitary adenomas (FIPA), multiple endo-
crine neoplasia type 1 and 4 (MEN1, MEN4), Carney complex,
McCune-Albright syndrome and X-linked acrogigantism.4-7 Mutations
of the aryl hydrocarbon receptor-interacting protein (AIP) gene (AIPmut)
account for 15%-20% of FIPA kindreds and are particularly important
in the pathogenesis of pediatric-onset PAs.8,9
Germline AIPmut-associated (AIPmut+) PAs are distinctive, pre-
senting usually as growth hormone (GH)-secreting PAs
(somatotropinomas) that are significantly larger, more invasive and occur
at a younger age than PAs without AIP mutations (AIPmut-).10 The first-
line treatment for sporadic somatotropinomas is transsphenoidal surgery,
which controls hormone hypersecretion in only about 50% of patients.11
For uncontrolled or recurrent disease, medical therapy with somatostatin
analogs (SSA) is used in most cases.12 As the response to SSA is depen-
dent on several molecular determinants, 10%-30% of patients do not
respond to this therapy and can require other therapies such as
pegvisomant or radiotherapy; novel therapeutic approaches (eg, metfor-
min and statins) are now being evaluated preclinically and in small patient
cohorts (reviewed in Reference 13). AIPmut + somatotropinomas are rel-
atively resistant to first-line medical treatment with SSA.10 The molecular
pathways that lead to this aggressive, treatment-resistant phenotype are
of great clinical relevance, but the specific pathway(s) are unclear.
AIPmut+ leads to impaired interaction with phosphodiesterase-4A5
(PDE4A5),14 dysregulated protein kinase A (PKA) function,15,16 and
disrupted regulation of the inhibitory G protein, Gαi2, which can increase
cyclic adenosine monophosphate (cAMP).17,18
Like many other human tumor types, the development of PAs can
be influenced by microRNAs (miRNAs); differential miRNA expression in
PAs is related to histological tumor subtypes, clinical behavior and treat-
ment responses.19-24 Interactions between miRNAs and normal, non-
mutated AIP have also been noted: miR-107 is overexpressed in
somatotropinomas and binds to and represses AIP in GH3 cells in vitro.25
As the effects of AIPmut per se on miRNA expression in human tumors
are unknown, we set out to determine the miRNA signature of AIPmut+
and AIPmut− PAs. Among the miRNAs we identified as being
upregulated in AIPmut+ PA tissues was miR-34a. We show that miR-34a
has pro-oncogenic functions in PAs, likely mediated by increased cyclic
adenosine monophosphate (cAMP) signaling, and that Gαi2 is a direct tar-
get of miR-34a and is differentially expressed in human PAs depending
on AIPmut status. We report for the first time that miR-34a upregulation
leads not only to increased cell proliferation and GH secretion in vitro,
but also induces resistance to the antiproliferative and hormonal effects
of the first-generation somatostatin analog, octreotide.
2 | MATERIALS AND METHODS
2.1 | Patient samples
For the current study, a total of 42 primary PAs were collected com-
prising 32 somatotropinomas and 10 prolactinomas. Twenty
somatotropinomas were negative for AIPmut (AIPmut−) and 12 were
AIPmut+. Three prolactinomas were AIPmut+and seven were AIPmut−.
What's new?
Germline mutations in the AIP gene are a significant cause of
inherited intracranial pituitary adenoma (PA). AIP mutation-
positive (AIPmut+) PAs are characterized by early tumor
onset, aggressive tumor behavior, and resistance to somato-
statin analogs (SSAs). Here, the microRNA-34a (miR-34a)
was found to be upregulated in AIPmut+ PA, where it corre-
lates with pro-oncogenic features, high cAMP levels, and
impaired response to octreotide, a first-generation SSA. In
vitro, miR-34a directly targeted GNAI2, the gene encoding
Gαi2, an inhibitor of cAMP synthesis known to be down-
regulated in AIPmut+ adenomas. Together, miR-34a and
Gαi2 may be valuable biomarkers for therapeutic stratifica-
tion of AIPmut+ patients.
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For miRNA array analysis, 22 PAs were used (10 AIPmut− and
12 AIPmut+). Among these samples, there were 12 somatotropinomas
(5 AIPmut− and 7 AIPmut+). A summary of the clinical characteristics
of the patients is reported in Table 1 and a list of the clinical features,
mutation status and the presence of LOH is provided in Table S1. In
line with previous results, the age at diagnosis was significantly lower
(Figure S1A) and the tumor size was significantly larger (Figure S1B) in
AIPmut+ compared to AIPmut− patients.
2.2 | RNA extraction and processing
RNA was extracted from the patient samples with the RNeasy Mini
Kit (#74104, Qiagen) and RNA concentration was determined by a
Spectrophotometer NanoDrop ND-1000 (Thermo Fisher Scientific,
Waltham, Massachusetts).
2.3 | DNA extraction and LOH analysis
To establish germline AIP status, DNA was isolated from peripheral
blood leukocytes and AIP was sequenced under conditions
described.8-10 Germline DNA was also studied for deletions in AIP using
multiplex ligand-dependent probe amplification (MLPA), but no germline
deletions were present. DNA was also extracted following microdis-
section of FFPE tissue sections of pituitary adenomas and evidence of
allelic loss to demonstrate loss of heterozygosity (LOH) was performed
using MLPA (SALSA P244 probemix, MRC-Holland, The Netherlands).
2.4 | Microarray hybridization and data analysis
RNA samples were analyzed by the GeneChip miRNA 1.0 array
(Affymetrix/Thermo Fisher Scientific.), which is based on the Sanger
miRBase miRNA database v11 (April 15, 2008). Tumor tissue was iso-
lated from previously identified FFPE tissue sections with the RNeasy
FFPE Kit (#73504, Qiagen). Total RNA (250 ng) was labeled with the
FlashTag Biotin HSR kit (Genisphere) and hybridized. Staining and scan-
ning were done according to the Affymetrix expression protocol. Array
data was processed and annotated with the miRNA QC tool
(Affymetrix, version 1.0.33.0) using settings recommended by Gen-
isphere. Briefly, background was detected and removed by RMA global
background correction, followed by quantile normalization and summa-
rization using median polishing. Statistical analysis of the resulting
dataset was performed by utilizing the statistical programming environ-
ment R (R Development Core Team 2011 R: A Language and Environ-
ment for Statistical Computing. Vienna, Austria: The R Foundation for
Statistical Computing) implemented in CARMAweb.26 Genewise testing
for differential expression was done employing the limma t-test and
Benjamini-Hochberg multiple testing correction. All gene sets were fil-
tered for true detection in at least half of the samples in at least one
group per comparison. For technical replicates, the average was used
for calculations. Functional annotations were generated through the
use of QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood
City, www.qiagen.com/ingenuity) using Fisher's exact test P values.
Input was regulated eight miRNAs from somatotropinomas (FC > 1.5x,
P < .002; miR-383 was excluded). Heat maps were generated in R.
2.5 | Plasmid constructs and antibodies
The p.R271W mutation was introduced by site-directed mutagenesis
(QuikChange II Site-Directed Mutagenesis Kit, #200523, Agilent
Technologies) in the wild-type human AIP cDNA cloned in a pCMV-
Myc backbone. The mutagenesis was verified by sequencing.
A fragment containing the predicted seed match and the mutated
seed match of miR-34a in the rat 30UTR of the GNAI2 gene was gen-
erated by annealing two oligos that represent the top and bottom
TABLE 1 Summary of the clinical
characteristics of the PA patients that
participated in the study
Number of patients (n = 42) AIPmut− (n = 27) AIPmut+ (n = 15)
n % n % n %
Sex
Female 20 48 17 63 3 20
Male 22 52 10 37 12 80
Age at diagnosis
<30 years 20 48 6 22 14 93
≥30 years 22 52 21 78 1 7
Tumor size
Micro 8 19 8 30 0 0
Macro 30 71 17 63 13 87
Giant 4 10 2 7 2 13
Invasion
No 21 50 17 63 4 27
Yes 21 50 10 37 11 73
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strand of the fragment. After oligo annealing, the fragments were
cloned in a psiCHECK-2 backbone (#C8021, Promega).
Primers and Oligos for cloning and mutagenesis are listed in
Table S2.
Primary antibodies are listed in Table S3.
2.6 | Quantitative real-time polymerase chain
reaction
RNA was extracted using RNeasy Mini Kit (#74104, Qiagen) or with
the Maxwell 16 LEV simplyRNA Purification Kit (#AS1270, Promega)
following the manufacturer's instructions. Quantitative real-time poly-
merase chain reaction (qRT-PCR) was performed using TaqMan
inventoried primers and probes (Applied Biosystems, Foster City,
California) for the indicated genes, as described previously.27
The differential expression of selected miRNAs was validated by
qRT-PCR. RNA was isolated using the miRNeasy Mini Kit (#217004,
Qiagen) and miRNA concentration was determined as described
before. Synthesis of cDNA was performed by TaqMan miRNA
Reverse Transcription Kit (#4366596, Applied Biosystems) and primer
sets for the respective miRNAs (Applied Biosystems). For qRT-PCR
miRNA primer sets (Applied Biosystems) for the indicated miRNAs
were used. All reactions were performed in triplet PCR reactions with
U6 snRNA (#4427975, Applied Biosystems) as an endogenous control
using a comparative Ct method.
2.7 | Cell culture and transient transfections
GH3 cells (RRID:CVCL 0273; Rattus norvegicus mixed GH-prolactin
secreting PA cell line), MEFs from AIP knockout mice (MEF AIP −/−)
(RRID:CVCL UJ02), HEK293 cells (RRID:CVCL 0045) and GH4C1 cells
(RRID:CVCL 0276) clone of GH3 with little or no detectable levels of
growth hormone) were maintained in culture as described in Table S4.
Cell lines were purchased by LGC Promochem, whereas AIP−/− MEFs
were established in the laboratory of A. Karhu. All miRNA mimics used
and inhibitors with respective controls are listed in Table S5.
MEF AIP −/− were transiently transfected with AIP plasmids and
co-transfected with AIP plasmids and miRNA hairpin inhibitors (25 nM)
with the 4D-Nucleofector System X unit (Lonza Group AG) and the P4
Primary Cell 4D-Nucleofector X Kit L (#V4XP-4012, Lonza Group AG).
Electroporation was conducted using the pulse code CZ-167.
GH3 cells were transiently transfected with 150 nM miRNA mimics
(miRIDIAN unspecific control mimic; miRIDIAN microRNA rat rno-miR-
34a mimic; miRIDIAN microRNA rat rno-miR-145 mimic, from Dhar-
macon) or hairpin inhibitors (miRIDIAN microRNA rat rno-miR-34a inhib-
itor, from Dharmacon) using the 4D-Nucleofector System X unit and the
SF Cell Line 4D-Nucleofector X Kit L (#V4XC-2012, Lonza Group AG).
Electroporation was conducted using the pulse code DS-131.
HEK293 cells were authenticated within the last 3 years by
DSMZ (Braunschweig) using short tandem repeat profiling. HEK293
cells were plated 24 hours before transfection in 24-well-plates at a
density of 0.05 × 106 cells per well. The cells were transiently trans-
fected with Lipofectamine 3000 Transfection Reagent (#L3000015,
Thermo Fisher Scientific Inc.) according to the manufacturer's instruc-
tions with 1 μg of the vector and 150 nM of either negative control
inhibitor or anti-miR-34a.
All cell lines were routinely tested for mycoplasma contamination
using the PCR Mycoplasma Test Kit (#PK-CA91-1048, PromoKine)
and found to be mycoplasma-free.
2.8 | Drug treatments
Cells were treated with 25 μg/mL cycloheximide (#C4859, Sigma-
Aldrich) and 10 μM epoxomycin (EPOX, #BML-PI127-0100, Enzo Life
Sciences) in complete medium for the indicated times.
For therapy response, cells were treated with 10 or 100 nM
octreotide (kindly provided by Italfarmaco SpA) in serum-free medium
for the indicated times.
2.9 | Protein extraction and Western blotting
Cells were collected at the indicated time points and lysed in radio-
immunoprecipitation assay (RIPA) buffer (#R0278, Sigma-Aldrich) sup-
plemented with protease (#04693124001, Roche Diagnostics) and
phosphatase inhibitors (#04906845001, Roche Diagnostics). Protein
concentrations were determined by the Pierce BCA Protein Assay Kit
(#23225, Thermo Fisher Scientific Inc.). Equal protein amounts were
separated on 10% SDS-PAGE gels. Antibodies were applied at 4C
overnight incubation (primary antibody) and 1-hour incubation (sec-
ondary antibody) at room temperature. Proteins were visualized by
the SuperSignal West Pico Chemiluminescent Substrate Kit (#34080,
Thermo Fisher Scientific Inc.).
2.10 | Functional characterization of transfected
cells
Cell viability was assessed by a colorimetric assay using Wst-1 reagent
according to the manufacturer's recommendations (#11644807001,
Roche, La Roche Ltd).
Migration assays were performed using 24-well plates with
uncoated polycarbonate membrane inserts (#353097, BD Biosci-
ences). Cells were allowed to migrate for 24 hours. Membranes were
stained by 1.5% (w/v) Toluidin Blue (#115930, Merck), fixed with
Methanol (#106009, Merck) and mounted on glass slides with Pertex
mounting medium (#41-4010-00, MEDITE GmbH). Images were
recorded using an Olympus BX43 microscope.
Clonogenic potential of the cells was monitored by seeding the
miRNA overexpressing cells at a low density of 1 × 103 cells per well
in six-well plates. After 8 days, colonies were stained with 0,3% Crys-
tal Violet in 30% ethanol and those with a diameter >100 μm were
counted.
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GH3 cells transfected with miRNA mimics were plated in 96-well
plate at a density of 1.5 × 105 cells per well and six wells per group.
For assessment of apoptosis in the cells, Caspase-Glo 3/7 Assay
(#G8090, Promega) was performed according to the manufacturer's
instructions.
2.11 | Immunoassays
Transfected GH3 cells (7 × 105 per well) were plated in six-well plates
and 24 hours later, cAMP levels were determined by using an ELISA
kit (#ADI-900-006, Enzo Life Sciences) according to the manufac-
turer's protocol.
After transfection GH3 cells were plated at a density of 8 × 104 cells
per well in a 24-well plate in serum-free medium. After 24 hours, cells
were treated with 100 nM Octreotide for additional 48 hours. The
supernatant was then collected and GH was measured using a
Rat/Mouse ELISA Kit (#EZRMGH-45K, Merck Millipore) whereas prolac-
tin was measured with the rat ELISA Kit (#589701, Cayman Chemical).
2.12 | miRNA target prediction
The targets of the differentially expressed miRNAs were predicted by
four different prediction tools, TargetScan 7.0, miRANDA-mirSVR,
DIANA tools and PITA that take different parameters into consider-
ation (Table S6).
2.13 | Reporter gene assays
To conduct reporter gene assays, HEK293 cells were lysed 24 hours
after transfection according to the protocol of the Dual-Luciferase
Reporter (DLR) Assay Kit (#E1980, Promega). Subsequently the
reporter assay was performed according to the manufacturer's
instructions.
2.14 | Immunohistochemistry and scoring
Immunhistochemical stainings were performed on an automated
immunostainer (Ventana Medical Systems) as previously described.28
Primary antibodies were diluted in Dako REALTM antibody diluent
(Dako). Positive controls were included in each run. The slides were
counterstained with hematoxylin for 10 seconds and washed under
running water for 4 minutes. Images were recorded using an Olympus
BX43 microscope (Olympus).
For Gαi-2-immunohistochemistry (IHC) an Avidin-Biotin block
(AB-block) was used to decrease unspecific background staining. For
AIP-IHC the AB-block was not necessary.
IHC results were evaluated using a semiquantitative method that
assessed the staining intensity: − (negative), + (mild), ++ (moderate)
and +++ (strong). Slides were scored using a double-blind method by
two independent observers; the percentage of discrepancies was
below 3%. Images were recorded using a Hitachi camera HW/C20
installed in a Zeiss Axioplan microscope with Intellicam software (Carl
Zeiss MicroImaging).
2.15 | Statistical analysis
Results of the cell assays are shown as the mean of values obtained in
independent experiments ± SEM. Unpaired two-tailed Student's t-
test, Mann-Whitney test, one-way and two-way ANOVA were used
to detect significance between two series of data, and P < .05 was
considered statistically significant.
3 | RESULTS
3.1 | miRNA expression analysis in AIPmut+ vs
AIPmut− adenomas
Eighteen PAs were used for miRNA profiling (Figure S2) using GeneChip
miRNA arrays. In somatotropinomas, nine miRNAs were differentially
expressed (P < .002) in AIPmut+ compared to AIPmut− tumors and
showed a >1.5-fold change in expression. Six of them (miR-187, miR-
383, miR-145, miR-34a, miR-143, miR-1231) were significantly
upregulated and three (miR-195, miR-497, miR-26a) downregulated in
AIPmut+ vs AIPmut− (Figure 1A). In prolactinomas, three miRNAs were
regulated using the same criteria (Figure S3). One AIPmut+ prolactinoma
was excluded due to suboptimal RNA quality, and since only two sam-
ples remained, we focused on the somatotropinomas for subsequent
analyses. Some of the significant differentially expressed miRNAs have
previously been linked to PAs, including miR-26a, downregulated in pro-
lactinomas vs normal pituitary and upregulated in invasive adeno-
mas19,29; miR-143 and miR-145 were downregulated in ACTH-
secreting adenomas vs normal pituitary,19 and miR-383, downregulated
in invasive NFPAs.19 To obtain a functional annotation of the differen-
tially expressed miRNAs, we used Ingenuity Pathway Analysis. The most
enriched terms were cancer-related, followed by terms related to cell
cycle and cellular movement (Table S7), further supporting a role for the
differentially expressed miRNAs in tumors. To validate the miRNA array
results, we assessed the miRNAs with the highest differential expres-
sion (ie, miR-187, miR-383, miR-145, miR-34a and miR-195) by quanti-
tative qRT-PCR in somatotropinoma samples. These analyses confirmed
a significant upregulation of miR-187, miR-145 and miR-34a and a down-
regulation of miR-195 in AIPmut+ vs AIPmut− somatotropinomas
(Figure 1B-F), whereas the differential expression of miR-383 could not
be validated.
3.2 | Effects of mutant AIP in MEFs of Aip−/− mice
Given that the AIP-R271W mutation was predominant in our cohort
(and is the most frequent missense AIPmut reported) we focused on
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this mutated AIP protein. We first determined whether ectopic expres-
sion of the AIP-R271W variant affects cell proliferation. To avoid inter-
ference from endogenous wild-type AIP, MEFs from Aip−/− mice were
transfected with AIP wild-type (wt) or AIP-R271W and cell proliferation
was measured 24, 48 and 72 hours later. At the 24 hours time point,
AIP-R271W increased cell proliferation vs AIP-wt (Figure 1G). This effect
was no longer present 48 hours after transfection (Figure 1G). Western
blot analysis revealed that the AIP-R271W protein was detectable only
up to 24 hours after transfection, while AIP-wt was present throughout
the duration of the experiment, suggesting that mutant AIP is less stable.
Treatment of transfected cells with cycloheximide (CHX) confirmed this
hypothesis: while AIP-wt showed no decrease up to 20 hours post-
transfection, the level of AIP-R271W started to decrease already after
4 hours (Figure S4A). Treatment of transfected MEFs with both CHX
and the proteasome inhibitor epoxomycin (EPOX) established that the
degradation of mutant AIP is mediated, at least in part, by the
proteasome (Figure S4B). This is in agreement with previously reported
in vitro data analyzing the half-life of various AIPmut, including
R271W.30 Therefore, all subsequent experiments were conducted
24 hours after transfection and plasmid DNA was adjusted to reach
equal protein levels for AIP-wt and AIP-R271W. Taken together, the
ectopic expression of AIP-R271W promoted the proliferation of Aip−/−
MEFs despite being present at low levels.
3.3 | Regulation of miRNA expression by mutant
AIP in Aip−/− MEFs
To demonstrate a direct link between the presence of mutant AIP and dif-
ferential miRNA expression, Aip−/− MEFs were transiently transfected with
AIP-wt or AIP-R271W and the levels of selected differentially expressed
miRNAs were assessed by qRT-PCR. In line with the array analyses,
miR-34a and miR-145 were significantly upregulated upon transfection of
AIP-R271W vs AIP-wt (Figure 1H,I). In contrast, the level of expression of
miR-195 and miR-187 was similar in both conditions (Figure 1J,K). Thus,
miR-34a and miR-145 were chosen for further in vitro characterization.
3.4 | Short-term upregulation of miR-145 and miR-
34a promotes oncogenic features in PA cells
We next investigated whether upregulation of miR-34a and/or miR-
145 (mimicking AIPmut+ tumors) affects the phenotypic features of
PA cells. GH3 cells (derived from a rat GH/prolactin-secreting ade-
noma) were transfected with specific mimics for mature miR-34a and
miR-145, and functional assays were performed assessing prolifera-
tion, clonogenic potential, migration and apoptosis (Figure 2A-D).
Short-term overexpression of both miRNA mimics (24 hours)
increased GH3 cell proliferation when compared to cells transfected
with an unspecific control miRNA mimic (Figure 2A). GH3 cells over-
expressing miR-34a migrated significantly more than the control ones,
whereas transfection of miR-145 mimic had no effect on cell migra-
tion (Figure 2B). miR-34a and miR-145 overexpression decreased
GH3 cells apoptosis, with miR-34a having the stronger effect
(Figure 2D). miR-34a, but not miR-145, upregulation increased by
2-fold the clonogenic potential of GH3 cells vs cells transfected with
unspecific miRNA control (Figure 2C). Altogether, high levels of miR-
34a increased proliferation, clonogenicity, migration and suppressed
apoptosis of PA cells. miR-145 upregulation only moderately pro-
moted proliferation and decreased apoptosis.
3.5 | miR-34a but not miR-145 overexpression
impairs the response to octreotide
Acromegaly and gigantism patients carrying AIP mutations poorly
respond to somatostatin receptor subtype 2 (SST2)-specific SSAs such
as octreotide and lanreotide; consequently, GH normalization and
tumor shrinkage are limited in AIPmut+ -related acromegaly when
compared to AIPmut− patients.10 Given that mutated AIP upregulates
miR-34a and miR-145, we assessed whether the levels of these
miRNAs affect the ability of PA cells to respond to octreotide. GH3
cells were transfected with miRNA mimics as above, treated with
octreotide for 72 hours and then cell proliferation was measured.
Cells overexpressing the unspecific miRNA control and treated with
octreotide showed decreased proliferation (−37%) vs untreated cells
(Figure 2E), as previously reported.31,32 A comparable reduction in cell
proliferation was also observed in cells overexpressing miR-145 and
treated with octreotide (−49%), whereas no suppression of cell prolif-
eration was detected upon miR-34a upregulation (Figure 2E). This
suggests that high miR-34a levels abolished the octreotide-dependent
inhibition of PA cell proliferation.
Octreotide suppresses GH and prolactin (PRL) secretion from
GH3 cells in vitro.32 Overexpression of AIP-wt in GH3 cells reduces
GH secretion by decreasing cAMP levels.33 Thus, we measured GH in
the supernatant of GH3 cells transfected with the above miRNA
F IGURE 1 miRNA expression profiles of AIPmut− and AIPmut+ PAs and validation. A, Heat map of the most differentially expressed miRNAs
(P < .002, fold-change > 1.5×) in somatotropinomas (n = 11). Yellow (blue) indicates higher (lower) expression level (z-scales to mean expression
per row). B-F, Validation of selected miRNAs in human somatotropinomas by qRT-PCR. The line represents the mean value and results are
reported as the mean ± SEM. Each dot represents an AIPmut− PA, each filled square represents an AIPmut+ PA. *P < .05; **P < .01; n.s., not
significant (by Mann-Whitney test). G, Aip−/− MEFs were transfected with empty vector, AIP-wt or AIP-R271W constructs. Cell viability was
assessed 24, 48 and 72 hours after transfection. The experiment was independently performed three times each with six technical replicates and
values are reported as the mean ± SEM. Only the statistical differences between AIP-wt and AIP-R271W are indicated. *P < .05; ***P < .001; n.s.,
not significant (by two-way ANOVA). H-K, Aip−/− MEFs were transfected with empty vector, AIP-wt or AIP-R271W constructs. Expression
levels of selected miRNAs were measured 24 hours post-transfection. The experiments were performed with 2 to 4 biological and 2 to
3 technical replicates and results are reported (±SEM). *P < .05; **P < .01; n.s., not significant (by one-way ANOVA). Ev, empty vector
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mimics and treated with octreotide for 48 hours (Figure 2F). For sake
of completeness, we also measured PRL levels in the cells supernatant
(Figure 2G). As expected, octreotide incubation led to a significant
decrease in both GH and PRL secretion in cells transfected with the
unspecific miRNA control (Figure 2F,G). A similar result was obtained
in cells overexpressing miR-145 (−44% and −22%, respectively;
Figure 2F,G). In contrast, upregulation of miR-34a led to a loss of
octreotide-mediated suppression of both GH and PRL secretion
(Figure 2F,G), indicating that high miR-34a levels mediated the lack of
response of GH3 cells to octreotide treatment.
3.6 | Effects of the validated miRNAs on cAMP
signaling in PA cells
Increased cAMP levels are an important hallmark of neuroendocrine
tumors including PAs.34 Moreover, cAMP signaling is dysregulated
after AIP inactivation in mice and this associated with somatotrope
tumorigenesis.17 Therefore, we measured cAMP levels in GH3 cells
transfected with miR-145 or miR-34a mimics, or with an unspecific
miRNA control. Overexpression of miR-34a almost doubled the intra-
cellular levels of cAMP in GH3 cells when compared to cells trans-
fected with the unspecific negative control, whereas ectopic miR-145
expression had no effect on the amount of cAMP (Figure 2G).
cAMP has been reported to exert its mitogenic effect in somato-
troph cells via phosphorylation of extracellular signal-regulated
kinases (ERK1/2).35,36 Therefore, we assessed total and phosphory-
lated ERK1/2 by western blotting. Overexpression of both miR-34a
and miR-145 increased the levels of phosphorylated ERK1/2 com-
pared to both untransfected and unspecific control-transfected cells
(Figure 2H,I). The increase in phospho-ERK1/2 was more pronounced
following miR-34a overexpression (vs miR-145) and this paralleled the
higher intracellular levels of cAMP (Figure 2G).
3.7 | Guanine nucleotide-binding protein G(I)
subunit alpha-2 (GNAI2) as a novel predicted target
gene of miR-34a
AIPmut in PAs leads to upregulation of miR-34a, which in turn pro-
motes proliferation and cAMP signaling. To better understand these
effects, we identified predicted miR34a target genes using four differ-
ent prediction tools (Table S6). Following the criteria outlined above
(Materials and Methods), we selected several putative target genes
(Table S8). As TargetScan considers only seed match and conservation
for target prediction (Table S6), we excluded targets predicted only by
algorithm alone. We focused on genes involved in cAMP signaling
(Table S9), which included several phosphodiesterases (PDE3a, PDE4A,
PDE5a, PDE7b) and G-protein alpha subunit family members (GNAO1,
GNAI2, GNAI3, GNAQ; Table S9). GNAI2 and GNAI3 are interesting
candidates as they encode inhibitory Gαi subunits which lead to
decreased cAMP levels. To verify whether these genes were regulated
by miR-34a, we transfected GH3 cells with the miR-34a mimic (for
overexpression) or a specific anti-miR-34a (for downregulation) and
assessed the level of GNAI2 and GNAI3. The modulation of miR-34a
levels were confirmed by qRT-PCR at 24 hours and 48 hours post-
transfection (Figure S5). Aip was previously shown to be regulated by
miR-34a37 and was thus included (Figure 3A,D). miR-34a
overexpression decreased Gnai2 mRNA levels by about 30% vs
nonspecific miRNA negative control transfected cells (Figure 3B);
miR-34a downregulation increased Gnai2 expression by about
1.5-fold (Figure 3E). No changes in Gnai3 levels were observed after
miR-34a modulation (Figure 3C,F).
Then, we tested whether miR-34a directly targets Gnai2 using
reporter gene assays. Given that a seed match for miR-34a in the
3'UTR region of rat Gnai2 was predicted, we cloned this sequence into
the psiCHECK-2 vector upstream of the firefly luciferase gene
(Figure 3G). This construct was then transfected into HEK293 cells
F IGURE 2 mir-34a promotes tumorigenic behavior in PA cells. A-D, GH3 cells were transfected with an unspecific miRNA mimic (unspecific
control) or with specific mimics for mature miR-34a or miR-145. All assays were performed 24 hours after transfection. The values are normalized
against the negative control arbitrarily set to 100%. Results are reported as the mean ± SEM. A, Cell viability was assessed by the WST-1 assay.
The experiment was independently performed three times each with six technical replicates. B, Migration assays were conducted using the
Boyden chamber and the migrated cells were counted. The experiment was independently performed twice each time with three technical
replicates. C, Transfected GH3 cells were plated and selected. Seven days later the colonies were fixed, stained and those that reached a diameter
>100 μm were counted. The experiment was independently performed three times each with 3 to 4 technical replicates. D, Caspase 3/7 activity
was measured to assess apoptosis. The experiment was independently performed three times each with two technical replicates. Results are
reported as the mean ± SEM *P < .05; **P < .01; ***P < .001; n.s., not significant (by one-way ANOVA). E-G, effect of miR-34a and miR-145 on
cell viability and GH or PRL secretion of GH3 cells following octreotide treatment. GH3 cells were transfected with an unspecific miRNA
(unspecific control) or with specific mimics for mature miR-34a or miR-145 and subsequently treated with 10 nM octreotide (Oct) for 72 hours or
100 nM Oct for 48 hours. Cell viability (E) and GH (F) or PRL (G) secretion were then measured using the WST-1 assay (E) or ELISA (F,G),
respectively. The experiments were independently performed three times each with six (e) or two (F, G) technical replicates. The values are
normalized against the untreated unspecific control arbitrarily set to 100%. Results are reported as the mean ± SEM. *P < .05; **P < .01;
***P < .001; n.s., not significant (by two-way ANOVA). H-L, effect of miR-34a and miR-145 on cAMP levels and ERK1/2 activation. H, GH3 cells
were transfected with an unspecific miRNA (unspecific control) or with specific mimics for mature miR-34a or miR-145. Intracellular cAMP levels
were measured 24 hours after transfection. The experiment was independently performed five times each with two technical replicates. The
values are normalized against the negative control arbitrarily set to 100%. Results are reported as the mean ± SEM. I, In samples parallel to (H),
western blot was performed 24 hours after transfection using an anti-p-ERK-1/2 antibody and an anti-ERK-1/2 antibody. The blot shown is
representative of 2 independent experiments with similar results. L, Ratio of the band intensities of the blots (n = 2) described in (H). Results are
reported as the mean ± SEM. ***P < .001; n.s., not significant (by one-way ANOVA). UT, untransfected; UC, unspecific control
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together with an unspecific miRNA inhibitor or the anti-miR-34a, and
luciferase activity was monitored. A decrease in luciferase activity was
detected between cells cotransfected with empty vector and
unspecific control miRNA inhibitor vs cells cotransfected with empty
vector and anti-miR-34a inhibitor (Figure 3I). In contrast, anti-miR-34a
increased the luciferase activity of the construct containing the Gnai2
F IGURE 3 Legend on next page.
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seed match vs unspecific miRNA inhibitor by almost 30% (Figure 3I).
Deletion of the seed region abolished the anti-miR-34a-mediated reg-
ulation of luciferase activity, thereby confirming that this miRNA does
bind to the seed sequence in Gnai2 (Figure 3H,I).
3.8 | Gαi2 expression is reduced in human AIPmut
+ PAs
AIPmut+ PAs show an increase in miR-34a expression, which in turn
regulates Gnai2 expression. Thus, we next investigated Gαi2 (and AIP)
expression by immunohistochemistry (IHC) on AIPmut− and AIPmut+
samples (Table S1). Slides were then scored semiquantitatively for
staining intensity (Figure 4A). In total, 38 human PA tumors were
scored for AIP expression and 30 (n = 18 AIPmut−; n = 12 AIPmut+)
for Gαi2 expression (Figure 4B,C). We found that levels of Gαi2 were
significantly lower in AIPmut+ vs AIPmut− tumors (P < .05; Figure 4D),
whereas there was no statistically significant difference in AIP staining
between the two sample groups (Figure 4E). By only considering the
somatotropinomas (n = 13, AIPmut−; n = 9, AIPmut+), decreased Gαi2
staining in AIPmut + tumors was even more pronounced (P < .01;
Figure 4F). Again, no significant difference in AIP expression was
detected between AIPmut+ and AIPmut− somatotropinomas
(Figure 4G). Not always tumors of AIPmut+ patients lacked AIP
expression (Figure S6). A positive correlation between Gαi2 and AIP
was found when all samples (AIPmut+ and AIPmut−) were analyzed
together (Figure S7A). A detailed analysis of each group revealed that
the positive correlation could only be observed in AIPmut−
(Figure S7B), but not in AIPmut+ (Figure S7C) samples.
In AIPmut− PAs, invasive tumors have a lower expression score
of both, AIP and Gαi2 (Figure S7A,C), whereas no difference in
expression scores of either protein was seen in the AIPmut+ patient
group (Figure S8).
4 | DISCUSSION
Acromegaly is a rare and disfiguring disease that, if inadequately
treated, carries significant morbidity and increased mortality.12
Resistance to medical therapy with SST2-specific SSAs like octreotide
or lanreotide is an important impediment to hormonal control in acro-
megaly. AIPmut in acromegaly leads to such SSA resistance, which has
a major clinical impact on patients as AIPmut are also associated with
young-onset, large and invasive PAs.10 The mechanisms to explain this
phenotype are therefore of high clinical relevance. We report here for
the first time that AIPmut+ somatotropinomas have a distinct miRNA
profile of miR-34a upregulation, a well-known miRNA that can func-
tion as an oncomiR in multiple cancers. Loss of AIP due to mutation
led to increased miR-34a, which was associated with increased cAMP
and low Gαi2 expression. Importantly, miR-34a dysregulation also
recapitulated the SSA-resistant phenotype of human AIPmut, with
blunting of the antiproliferative and GH secretory effects of
octreotide. This suggests that the aggressive and therapeutically-
resistant features of AIPmut in PA could be mediated by dysregulated
miR-34a.
Nine miRNAs were differentially expressed between AIPmut+
and AIPmut− somatotropinomas, five of which were validated by
qRT-PCR: miR-187, miR-145, miR-34a, (upregulated in AIPmut+) and
miR-195 (downregulated). Among the AIPmut+ PA samples we used,
the missense mutation p.R271W was the most frequent and is a
recurrent mutation clinically.38 As p.R271W is known to affect AIP
function,39 we used this variant to verify the causal relationship
between mutant AIP and miRNA expression by ectopically over-
expressing AIP-R271W in Aip-deficient MEFs. AIP-R271W was pre-
sent at much lower levels than wild-type AIP due to enhanced
degradation in part through the proteasome. This accords with
Hernandez-Ramirez et al who reported decreased stability of
AIP-R271W in HEK293 cells.30 Despite its short half-life, ectopic AIP-
R271W promoted AIP−/− MEFs proliferation. This effect was accom-
panied by specific upregulation of miR-34a and miR-145, thereby
establishing a relationship between AIPmut and expression of these
two miRNAs.
In rat pituitary GH3 cells, upregulation of miR-34a promoted
migration and inhibited apoptosis, whereas miR-145 moderately
increased cell viability and decreased apoptosis. Furthermore,
octreotide inhibited proliferation and GH secretion in GH3 cells,
whereas, miR-34a overexpression counteracted this. Therefore, stim-
ulation of miR-34a expression by mutant AIP leads to resistance to
F IGURE 3 miR-34a directly targets Gnai2 in GH3 cells. GH3 cells were just pulsed without DNA, or transfected with an unspecific miRNA
(unspecific control), with a specific mimic for mature miR-34a (A-C) or with an antagonist of miR-34a (D-F). mRNA levels of Aip (A, D), Gnai2 (B,
E), or Gnai3 (C, F) were determined 24 hours after transfection by qRT-PCR. Each amplification was independently performed 3 to 6 times each
with two technical replicates. The values are normalized against the unspecific control arbitrarily set to 100%. Results are reported as the mean
± SEM. ***P < .001; n.s., not significant (by one-way ANOVA). G, Sequence of the DNA fragment cloned into the psiCHECK-2 luciferase vector
(GNAI2 oligos) which contains the predicted seed match of miR-34a (pink) located in the 30 UTR of the rat Gnai2 gene (yellow). H, Sequence of
the DNA fragment cloned into the psiCHECK-2 luciferase vector (GNAI2 oligos) which contains a deletion of the predicted seed match of miR-
34a (pink) in the 30 UTR of the rat Gnai2 gene (yellow). I, HEK293 cells were co-transfected with the empty vector and an unspecific miRNA
inhibitor (unspecific control inhibitor) or a specific antagonist for miR-34a (anti-miR34a), with the seed match-containing vector (shown in a) and
either the unspecific miRNA or the specific anti-miR34a or with the mutated seed match-containing vector (shown in b) with the unspecific
miRNA or the specific anti-miR34a. The experiment was independently performed three times each with three technical replicates. The values are
normalized against an untransfected control (not shown in the graph). Results are reported as the mean ± SEM. **P < .01; ***P < .001; n.s., not
significant (by two-way ANOVA). UT, untransfected; UT Nuc, untransfected Nucleofector; UC, unspecific control; ev, empty vector; sm, seed
match; mut sm, mutated seed match
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F IGURE 4 Gαi2 expression levels are reduced in in human AIPmut + PAs. A, Immunohistochemical staining of four representative primary PAs for
Gαi2 and AIP. The samples cover the range of staining intensities observed (0; +; ++; +++). Antibodies anti-Gαi2 (1/200) and anti-AIP (1/1000) were
used. Original magnification: ×200; scale bar = 20 μm. B,C, Staining intensities of the samples that could be scored for Gαi2 (B, n = 30) or AIP (C,
n = 38). Samples are divided in AIPmut− and AIPmut+ PAs. Expression of AIP and Gαi2 in human AIPmut− and AIPmut+ PAs. D-E, Gαi2 (D) and AIP
(E) staining intensities in AIPmut− and AIPmut+ samples. F-G, Gαi2 (F) and AIP (G) staining intensities in AIPmut− and AIPmut+ somatotropinomas.
Results are reported as the mean ± SEM. *P < .05; **P < .01; n.s., not significant (by unpaired two-tailed Student's t-test)
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octreotide treatment, thereby recapitulating the clinical phenotype of
AIPmut+ PA patients.
Both miR-34a and miR-145 have been implicated in various
human tumors. miR-145 is co-transcribed with miR-143 and both
have been described as a tumor suppressive miRNAs in
corticotropinomas and craniopharyngioma.22,40 In PAs, mir-145
inhibits mTOR signaling in invasive tumors, sensitizes prolactinoma
cells to bromocriptine, is downregulated in invasive NFPAs and its
overexpression reduces proliferation and invasion of NFPA cells
in vitro.23,41,42 miR-145 can, however, also foster tumor development:
knockout of the miR-143/miR-145 cluster reduced tumor number and
tumor area, and increased angiogenesis in a lung cancer mouse
model.43
miR-34a, together with miR-34b and miR-34c, are transcription-
ally regulated by p53. miR-34a was initially considered a tumor sup-
pressor since it is downregulated in several cancers, and reduces
proliferation and induces apoptosis of tumor cells.40,44,45 However,
recent evidence also points to a pro-oncogenic role for miR-34a as it
is overexpressed in gastric cancer and brain tumors, among
others.46-48 miR-34a plays a proproliferative and antiapoptotic role in
vascular and lymphoid tissues,49-51 and it was also found to induce
chemoresistance of osteosarcoma cells,52 and to promote genomic
instability.53 Therefore, miR-34a overexpression, a feature often
acquired during carcinogenesis, can play an oncogenic or tumor-
suppressive role in a tissue- and context-specific manner. In the nor-
mal pituitary, miR-34a is expressed at a level similar to that seen in
AIPmut− somatotropinomas, being overexpressed only in adenomas
with an AIP mutation (Figure S9). Interestingly, miR-34a was previ-
ously shown to have increased expression in non-AIPmut
somatotropinomas with low AIP protein levels, and to directly target
and inhibit AIP in a nonpituitary model (HEK293).37 While Denes
et al37 found only a modest effect of increased miR-34a on Aip protein
levels in GH3 cells, we have expanded this to show that AIPmut in PAs
specifically upregulates miR-34a, where it functions as an oncomiR.
In contrast to findings from our group and from Denes et al,37 it
was recently reported that long-term overexpression of miR-34a
decreases the proliferation of GH4C1 cells,54 a clone derived from
GH3 cells but that produces negligible amounts of GH. We did not
see changes in GH4C1 cell proliferation upon overexpression of miR-
34a up to 72 hours posttransfection (Figure S10) whereas in GH3
cells an increase in viability was already detectable 24 hours post-
transfection and lasted for several days (eg, in clonogenic assays). This
discrepancy suggests that miR-34a elicits different effects due to
underlying secretory and molecular heterogeneity between GH3 and
GH4C1 clones.55,56
Dysregulation of intracellular cAMP levels is a hallmark of func-
tioning endocrine tumors, including somatotropinomas, where cAMP
promotes cell division and GH secretion. A link between AIP and
cAMP has been established in that overexpression of wild-type AIP in
GH3 cells attenuates the forskolin-dependent increase in intracellular
cAMP and GH secretion, whereas silencing of endogenous Aip
increases cAMP concentration.33 Mechanistically, AIP interacts with
several members of the cAMP signaling cascade, including phosphodi-
esterases, the enzymes that deactivate cAMP, and G proteins, which
can either activate AC and increase cAMP (activating) or have the
opposite effects (inhibitory).16,57 In Aip-deficient MEFs, the inhibitory
Gαi2 and Gαi3 proteins do not inhibit cAMP synthesis, which suggests
that AIPmut-related pituitary tumorigenesis may occur via Gαi signal-
ing and cAMP.17 In this context, our finding that in PA cells AIPmut
leads to upregulation of miR-34a, which in turn increases intracellular
cAMP levels, offers an additional molecular mechanism relating defec-
tive AIP to cAMP production (Figure 5). Among the predicted miR-34a
F IGURE 5 Model of the effect of AIP deficiency on intracellular processes. A, Physiological and B, pathological (AIP mutation or loss) scenario
in which AIP deficiency leads to upregulation of miR-34a which in turn decreases Gαi2 levels. The inhibition of AC by Gαi2 is reduces and the AC
produces nonphysiological amounts of cAMP, which acts as an mitogenic signal in the cell
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targets was GNAI2 encoding Gαi2, which was confirmed to be a direct
target by reporter gene assays. Accordingly, miR-34a overexpression
in PA cells reduces GNAI2 levels, while its downregulation increases
them. A reduction intracellular levels of Gαi2 is expected to enhance
AC activity and to increase cAMP levels, which we observed.
Although a role has been suggested for Gαi2 in mediating the effects
of defective Aip, the mechanism was unknown as loss-of-function
mutations in GNAI genes are not seen in PAs.58 We demonstrate that
AIPmut decreases GNAI2 expression via miR-34a upregulation, and
this ultimately leads to increased AC activity as well as cAMP levels
(Figure 5).
In line with previous reports, we observed a trend towards a neg-
ative correlation between AIP levels and tumor size.59,60 Also, we con-
firmed that low AIP staining is associated with higher likelihood of
tumor invasion and AIPmut+ status did not predict AIP staining inten-
sity.61 We also found that AIPmut are associated with a reduction in
Gαi2 levels, thereby extending the findings of Tuominen et al.17 Simi-
lar to AIP, the levels of Gαi2 are reduced in invasive vs noninvasive
PAs only in the AIPmut+ group.
In summary, we show that AIPmut in GH-secreting PAs leads to
dysregulation of a specific subset of miRNAs, including miR-34a,
which is induced by AIPmut and has pro-oncogenic functions in
somatotropinomas through regulation of Gαi2 expression and
increased cAMP concentrations. As increased levels of miR-34a
impair the response of PA cells to octreotide, the lack of response of
AIPmut+ patients to first-generation SSAs might be mediated by
induction of miR-34a expression. These findings further support the
hypothesis that failure to inhibit cAMP synthesis due to down-
regulation of Gαi2 is key event in AIP-mediated pituitary tumorigen-
esis. Furthermore, this adds another level of complication to the
multifaceted role of AIP in PAs given that the increase of miR-34a
may lead to the regulation of other genes in addition to Gnai2. As
both high miR-34a and low Gαi2 levels are associated with resis-
tance to SSA therapy, they represent potential biomarkers that
could be used as evidence to personalize treatment choices and
improve outcomes in AIPmut patients.
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